Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.

Quanz M, Bender E, Kopitz C, Grünewald S, Schlicker A, Schwede W, Eheim A, Toschi L, Neuhaus R, Richter C, Toedling J, Merz C, Lesche R, Kamburov A, Siebeneicher H, Bauser M, Hägebarth A.

Mol Cancer Ther. 2018 Nov;17(11):2285-2296. doi: 10.1158/1535-7163.MCT-17-1253. Epub 2018 Aug 16.

PMID:
30115664
2.

BAY 1125976, a selective allosteric AKT1/2 inhibitor, exhibits high efficacy on AKT signaling-dependent tumor growth in mouse models.

Politz O, Siegel F, Bärfacker L, Bömer U, Hägebarth A, Scott WJ, Michels M, Ince S, Neuhaus R, Meyer K, Fernández-Montalván AE, Liu N, von Nussbaum F, Mumberg D, Ziegelbauer K.

Int J Cancer. 2017 Jan 15;140(2):449-459. doi: 10.1002/ijc.30457. Epub 2016 Oct 20.

3.

Identification of KCa3.1 Channel as a Novel Regulator of Oxidative Phosphorylation in a Subset of Pancreatic Carcinoma Cell Lines.

Kovalenko I, Glasauer A, Schöckel L, Sauter DR, Ehrmann A, Sohler F, Hägebarth A, Novak I, Christian S.

PLoS One. 2016 Aug 5;11(8):e0160658. doi: 10.1371/journal.pone.0160658. eCollection 2016.

4.

Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth.

Schöckel L, Glasauer A, Basit F, Bitschar K, Truong H, Erdmann G, Algire C, Hägebarth A, Willems PH, Kopitz C, Koopman WJ, Héroult M.

Cancer Metab. 2015 Oct 20;3:11. doi: 10.1186/s40170-015-0138-0. eCollection 2015.

5.

Expression analysis of proline rich 15 (Prr15) in mouse and human gastrointestinal tumors.

Meunier D, Patra K, Smits R, Hägebarth A, Lüttges A, Jaussi R, Wieduwilt MJ, Quintanilla-Fend L, Himmelbauer H, Fodde R, Fundele RH.

Mol Carcinog. 2011 Jan;50(1):8-15. doi: 10.1002/mc.20692.

PMID:
21061267

Supplemental Content

Loading ...
Support Center